BACKGROUND	Clade B DNA and recombinant modified vaccinia Ankara ( MVA ) vaccines producing virus-like particles displaying trimeric membrane-bound envelope glycoprotein ( Env ) were tested in a phase 2a trial in human immunodeficiency virus ( HIV ) - uninfected adults for safety , immunogenicity , and 6-month durability of immune responses .\